re: Ann: FDA agrees on potential regulatory p... Still going ahead as planned.
Taken from today's announcement:
ChemGenex is continuing its discussions with the FDA?s Center for Devices and Radiological Health towards approval of a diagnostic test for the T315I mutation, and the existing NDA for T315I positive CML patients who have failed imatinib remains open.